Loxo Oncology Inc (LOXO) Position Lowered by Amundi Pioneer Asset Management Inc.

Amundi Pioneer Asset Management Inc. trimmed its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 8.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,133 shares of the biopharmaceutical company’s stock after selling 6,438 shares during the period. Amundi Pioneer Asset Management Inc. owned approximately 0.25% of Loxo Oncology worth $8,553,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of LOXO. Cambridge Investment Research Advisors Inc. boosted its stake in Loxo Oncology by 26.8% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 2,917 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 617 shares during the period. Lazard Asset Management LLC acquired a new stake in Loxo Oncology during the 4th quarter worth $323,000. Sands Capital Management LLC acquired a new stake in Loxo Oncology during the 4th quarter worth $191,266,000. Pinnacle Associates Ltd. acquired a new stake in Loxo Oncology during the 4th quarter worth $451,000. Finally, UBS Asset Management Americas Inc. boosted its stake in Loxo Oncology by 2.0% during the 4th quarter. UBS Asset Management Americas Inc. now owns 211,234 shares of the biopharmaceutical company’s stock worth $17,782,000 after purchasing an additional 4,193 shares during the period.

In other news, VP Jennifer Burstein sold 1,700 shares of the firm’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $176.99, for a total value of $300,883.00. Following the completion of the sale, the vice president now owns 1,700 shares in the company, valued at approximately $300,883. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lori Anne Kunkel sold 5,000 shares of the firm’s stock in a transaction on Friday, April 20th. The stock was sold at an average price of $132.68, for a total transaction of $663,400.00. Following the completion of the sale, the director now owns 10,940 shares of the company’s stock, valued at approximately $1,451,519.20. The disclosure for this sale can be found here. Insiders sold a total of 153,878 shares of company stock valued at $25,611,475 in the last 90 days. Company insiders own 17.10% of the company’s stock.

A number of analysts recently weighed in on LOXO shares. Cann reiterated a “buy” rating and set a $122.00 price target on shares of Loxo Oncology in a research note on Thursday, March 1st. Zacks Investment Research cut shares of Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $135.00 price target on shares of Loxo Oncology in a research note on Friday, March 2nd. Citigroup reiterated a “buy” rating and set a $151.00 price target (up previously from $108.00) on shares of Loxo Oncology in a research note on Monday, March 5th. Finally, Morgan Stanley cut shares of Loxo Oncology from an “overweight” rating to an “equal weight” rating and set a $103.00 price target for the company. in a research note on Wednesday, March 21st. They noted that the move was a valuation call. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Loxo Oncology presently has an average rating of “Buy” and an average target price of $176.40.

LOXO stock opened at $169.76 on Thursday. Loxo Oncology Inc has a one year low of $69.00 and a one year high of $208.95. The firm has a market capitalization of $5.28 billion, a PE ratio of -31.97 and a beta of 2.45.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.01. The firm had revenue of $38.43 million during the quarter, compared to analyst estimates of $12.72 million. During the same quarter last year, the business posted ($0.96) EPS. equities research analysts expect that Loxo Oncology Inc will post 0.91 earnings per share for the current fiscal year.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply